Pertuzumab plus trastuzumab and docetaxel in HER2-positive metastatic breast cancer

Community Oncology

Volumn 9, Issue 2, 2012, Pages 42-44

  Abraham, Jame ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; PERTUZUMAB; PLACEBO; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CYTOTOXICITY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRY SKIN; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION;

EID: 84857478175     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmonc.2012.02.001     Document Type: Article

References (2)

1. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Has-mann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xeno-graft tumor models. Cancer Res. 2009;69(24):9330-9336.
2. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2011. [Epub ahead of print]. doi:10.1056/NEJMoa1113216.